Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Phosphatidylinositol 3-kinase-delta (PI3Kδ) signaling is critical for proliferation, survival, homing, and tissue retention of malignant B cells. Idelalisib, a selective oral inhibitor of PI3Kδ, has shown considerable single-agent activity in patients with heavily pretreated chronic lymphocytic leuk...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Hemasphere
Main Authors: Coutre, Steven E., Flinn, Ian W., de Vos, Sven, Barrientos, Jacqueline C., Schreeder, Marshall T., Wagner-Johnson, Nina D., Sharman, Jeff P., Boyd, Thomas E., Fowler, Nathan, Dreiling, Lyndah, Kim, Yeonhee, Mitra, Siddhartha, Rai, Kanti, Leonard, John P., Furman, Richard R.
Formato: Artigo
Idioma:Inglês
Publicado: Wolters Kluwer Health 2018
Assuntos:
Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6745995/
https://ncbi.nlm.nih.gov/pubmed/31723767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000039
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares